Tag: Alzheimer’s
Allopurinol May Cut Risk for Neurodegenerative Diseases
Allopurinol linked to 13 to 34 percent lower risk for Parkinson disease, Alzheimer disease, ALS
Medicare Spending Would Increase $2.0 to $5.1 Billion With Lecanemab
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636
Genetic Links Seen for HDL Cholesterol, Systolic BP With Alzheimer Disease
Genetically determined high-density lipoprotein cholesterol and systolic blood pressure linked to increased odds of Alzheimer disease
FDA Approves First Drug Meant to Ease Alzheimer Disease-Linked Agitation
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo
Experimental Drug for Alzheimer Disease Slows Decline in Thinking
Eli Lilly says drug slows memory and thinking declines in early symptomatic Alzheimer disease patients by more than a third
Suvorexant Cuts Tau Phosphorylation and Amyloid-β Concentrations
Proof-of-concept study is 'encouraging' for repurposing insomnia drug, authors say
Unawareness of Memory Decline Tied to Higher Risk for Progression
Findings show importance of decomposing the traditional awareness score
Women Have Higher Tau, Especially in Setting of Elevated Aβ
Later age at menopause and hormone therapy nonuse also associated with higher regional tau
U.S. Sets Up $300 Million Database for Alzheimer Disease Research
In creating the database, the goal is to provide something that can 'improve applicability and generalizability of findings'
Readmission Rates, Episode Costs Increased for Patients With Dementia
Cost of 30-day readmission and total 30-day episode costs higher for patients with Alzheimer disease and related dementias
